Hypothesis

Chronic IKKβ/NF‑κB activation in aging microglia not only suppresses GnRH transcription and depletes hypothalamic stem cells via Notch‑mediated apoptosis but also blocks the release of anti‑aging exosomal miRNAs from htNSCs, leading to a systemic decline in SIRT1 activity and accelerated inflammaging.

Mechanistic Basis

It's well established that microglial NF‑κB drives TNF‑α secretion, which amplifies NF‑κB signaling in adjacent GnRH neurons and htNSCs (2, 3). In htNSCs, NF‑κB directly represses the transcription of key miRNA‑processing genes (Dicer, Drosha) and upregulates RNase L, causing global miRNA depletion in secreted exosomes (1). Loss of exosomal miR‑21, miR‑124 and miR‑132 in CSF reduces SIRT1 expression in peripheral tissues (liver, muscle, adipose) through derepression of ACETYL‑CoA synthetase 2 and FOXO1, promoting NF‑κB activation and insulin resistance (4). SIRT1 normally deacetylates and inhibits IKKβ, establishing a feedback loop; its decline therefore accelerates microglial NF‑κB activation, creating a vicious cycle (5). The PI3K/Akt/FOXO3a axis can counteract this by phosphorylating FOXO3a, which promotes exosome biogenesis and miRNA loading, but its effectiveness wanes when NF‑κB overrides Akt signaling (5).

Testable Predictions

1. In aged mice, CSF exosomes from WT htNSCs will show a >60 % drop in miR‑21/124/132 content compared with young controls, and this loss will correlate with microglial IKKβ phosphorylation levels (p‑IKKβ) (2).
2. Pharmacological inhibition of IKKβ (e.g., with BMS‑345541) in aged mice will restore exosomal miRNA cargo, increase CSF SIRT1‑targeting activity, and improve peripheral insulin tolerance without altering GnRH secretion.
3. Conditional knockout of Dicer specifically in htNSCs will phenocopy the aging phenotype: reduced SIRT1 in liver/muscle, heightened serum TNF‑α, and accelerated frailty, even when microglial NF‑κB is genetically silenced.
4. Transplantation of young htNSCs engineered to overexpress miR‑124 will rescue SIRT1 expression in peripheral tissues and extend median lifespan by ~15 % in aged recipients.

Experimental Design

• Sample collection: Collect CSF from young (3 mo) and aged (18‑24 mo) C57BL/6 mice; isolate exosomes via ultracentrifugation; quantify miRNA by qPCR (miR‑21, miR‑124, miR‑132) and NF‑κB activation in microglia by Western blot for p‑IKKβ (2).
• Intervention: Treat aged mice with IKKβ inhibitor BMS‑345541 (10 mg/kg i.p., three times weekly for 4 weeks) or vehicle; assess exosomal miRNA rescue, CSF SIRT1‑dependent deacetylase activity (fluorometric assay), and peripheral glucose tolerance.
• Genetic models: Use htNSC‑specific Dicer‑flox crossed with Nestin‑CreER; induce deletion at 12 mo; measure SIRT1 target acetylation (p53‑AcK380) in liver, muscle, adipose; monitor serum cytokines and frailty index.
• Rescue: Transplant WT or miR‑124‑overexpressing htNSCs (1 × 10⁵ cells) into the third ventricle of aged Dicer‑cKO mice; track peripheral SIRT1 levels, locomotor activity, and survival.

Falsifiability: If IKKβ inhibition fails to restore exosomal miRNA levels or does not improve peripheral SIRT1 activity despite reducing microglial NF‑κB, the hypothesis is refuted. Likewise, if Dicer loss in htNSCs does not reproduce the systemic inflammaging phenotype, the proposed mechanistic link between htNSC exosome miRNA loss and aging is invalid.